INTRODUCTION AND HYPOTHESIS: Cell therapy for stress urinary incontinence (SUI) management has been experienced with encouraging results. METHODS: We conducted an open prospective study on 12 women presenting severe SUI with fixed urethra, after previous failed surgical management. Patients underwent intrasphincteric injections of autologous progenitor muscular cells isolated from a biopsy of deltoid muscle. Primary endpoint focused on safety (measurement of Q(max) variation after 3 months). Secondary endpoints assessed side effects and efficacy. RESULTS: No variation was diagnosed on Q(max) measurements. Efficacy data show that three of 12 patients are dry at 12 months, seven other patients are improved on pad test but not on voiding diary, and two patients were slightly worsened by the procedure. Quality of life was improved in half of patients. CONCLUSIONS: Cell therapy for severe multioperated cases of SUI is a mini-invasive, feasible, and safe procedure that can improve urinary condition in as a second line therapy.
INTRODUCTION AND HYPOTHESIS: Cell therapy for stress urinary incontinence (SUI) management has been experienced with encouraging results. METHODS: We conducted an open prospective study on 12 women presenting severe SUI with fixed urethra, after previous failed surgical management. Patients underwent intrasphincteric injections of autologous progenitor muscular cells isolated from a biopsy of deltoid muscle. Primary endpoint focused on safety (measurement of Q(max) variation after 3 months). Secondary endpoints assessed side effects and efficacy. RESULTS: No variation was diagnosed on Q(max) measurements. Efficacy data show that three of 12 patients are dry at 12 months, seven other patients are improved on pad test but not on voiding diary, and two patients were slightly worsened by the procedure. Quality of life was improved in half of patients. CONCLUSIONS: Cell therapy for severe multioperated cases of SUI is a mini-invasive, feasible, and safe procedure that can improve urinary condition in as a second line therapy.
Authors: M B Chancellor; T Yokoyama; S Tirney; C E Mattes; H Ozawa; N Yoshimura; W C de Groat; J Huard Journal: Neurourol Urodyn Date: 2000 Impact factor: 2.696
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Hideki Oshima; Thomas R Payne; Kenneth L Urish; Tetsuro Sakai; Yiqun Ling; Burhan Gharaibeh; Kimimasa Tobita; Bradley B Keller; James H Cummins; Johnny Huard Journal: Mol Ther Date: 2005-08-25 Impact factor: 11.454
Authors: L K Carr; D Steele; S Steele; D Wagner; R Pruchnic; R Jankowski; J Erickson; J Huard; M B Chancellor Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2008-06
Authors: Vivienne Kirchin; Tobias Page; Phil E Keegan; Kofi Om Atiemo; June D Cody; Samuel McClinton; Patricia Aluko Journal: Cochrane Database Syst Rev Date: 2017-07-25
Authors: Ron J Jankowski; Le Mai Tu; Christopher Carlson; Magali Robert; Kevin Carlson; David Quinlan; Andreas Eisenhardt; Min Chen; Scott Snyder; Ryan Pruchnic; Michael Chancellor; Roger Dmochowski; Melissa R Kaufman; Lesley Carr Journal: Int Urol Nephrol Date: 2018-10-15 Impact factor: 2.370
Authors: Christopher J Hillary; Sabiniano Roman; Sheila MacNeil; Wilhelm K Aicher; Arnulf Stenzl; Christopher R Chapple Journal: Nat Rev Urol Date: 2020-01-23 Impact factor: 14.432